US20220370413A1 - Formulations of psilocin that have enhanced stability - Google Patents
Formulations of psilocin that have enhanced stability Download PDFInfo
- Publication number
- US20220370413A1 US20220370413A1 US17/883,509 US202217883509A US2022370413A1 US 20220370413 A1 US20220370413 A1 US 20220370413A1 US 202217883509 A US202217883509 A US 202217883509A US 2022370413 A1 US2022370413 A1 US 2022370413A1
- Authority
- US
- United States
- Prior art keywords
- psilocin
- stable
- acid
- composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 title claims abstract description 271
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000009472 formulation Methods 0.000 title claims abstract description 16
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 title claims abstract 14
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000007385 chemical modification Methods 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 40
- 229940095064 tartrate Drugs 0.000 claims description 36
- -1 estolate Chemical compound 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000003860 storage Methods 0.000 claims description 14
- 239000002502 liposome Substances 0.000 claims description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 6
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims description 6
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- 229960000984 tocofersolan Drugs 0.000 claims description 6
- 239000002076 α-tocopherol Substances 0.000 claims description 6
- 235000004835 α-tocopherol Nutrition 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 229940126534 drug product Drugs 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000003595 spectral effect Effects 0.000 claims description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 3
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229940022663 acetate Drugs 0.000 claims description 3
- 229940045942 acetone sodium bisulfite Drugs 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- 229940050390 benzoate Drugs 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002023 chloroprocaine Drugs 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 3
- 229940009662 edetate Drugs 0.000 claims description 3
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 3
- 229950000206 estolate Drugs 0.000 claims description 3
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 3
- 239000000576 food coloring agent Substances 0.000 claims description 3
- 229940050411 fumarate Drugs 0.000 claims description 3
- 229960001731 gluceptate Drugs 0.000 claims description 3
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 claims description 3
- 229940050410 gluconate Drugs 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- 229940049906 glutamate Drugs 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229940001447 lactate Drugs 0.000 claims description 3
- 229940099584 lactobionate Drugs 0.000 claims description 3
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940049920 malate Drugs 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 3
- 229960003951 masoprocol Drugs 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 229960003194 meglumine Drugs 0.000 claims description 3
- 229940102396 methyl bromide Drugs 0.000 claims description 3
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 claims description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 3
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 3
- 229940049964 oleate Drugs 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229940014662 pantothenate Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229940001607 sodium bisulfite Drugs 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 229940001482 sodium sulfite Drugs 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 229940001474 sodium thiosulfate Drugs 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229950002757 teoclate Drugs 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000027109 Headache disease Diseases 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims 2
- 235000011149 sulphuric acid Nutrition 0.000 claims 2
- QVDSEJDULKLHCG-UHFFFAOYSA-N psilocybin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 68
- 238000000634 powder X-ray diffraction Methods 0.000 description 39
- 239000000243 solution Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 22
- 239000013078 crystal Substances 0.000 description 20
- 239000012458 free base Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 14
- 101150008710 TAAR1 gene Proteins 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000000399 optical microscopy Methods 0.000 description 12
- 150000003891 oxalate salts Chemical class 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 101100424383 Rattus norvegicus Taar4 gene Proteins 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000003890 succinate salts Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000001907 polarising light microscopy Methods 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036983 biotransformation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 150000003893 lactate salts Chemical class 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 150000002690 malonic acid derivatives Chemical class 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003892 tartrate salts Chemical class 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003991 Rietveld refinement Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000007942 carboxylates Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- PFODEVGLOVUVHS-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(C)CCN1C1=CC=C(C=O)C=C1 PFODEVGLOVUVHS-UHFFFAOYSA-N 0.000 description 2
- NLMQHXUGJIAKTH-UHFFFAOYSA-N 4-hydroxyindole Chemical compound OC1=CC=CC2=C1C=CN2 NLMQHXUGJIAKTH-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QPZFVYCQQOLROG-RNGZQALNSA-N CN(C)CCC1=CNC2=CC=CC(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)=C12 Chemical compound CN(C)CCC1=CNC2=CC=CC(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)=C12 QPZFVYCQQOLROG-RNGZQALNSA-N 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 101000946191 Galerina sp Laccase-1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 101150041420 Slc1a2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 101100115751 Trypanosoma brucei brucei dnaaf11 gene Proteins 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 229940022682 acetone Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001337 psychedelic effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- UUDLQDCYDSATCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)C(O)C(O)C(O)=O UUDLQDCYDSATCH-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 229910000809 Alumel Inorganic materials 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100480814 Arabidopsis thaliana TCP12 gene Proteins 0.000 description 1
- 101100206179 Arabidopsis thaliana TCP13 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 101000891399 Homo sapiens T-complex protein 11 homolog Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 241001237914 Psilocybe Species 0.000 description 1
- 241001062357 Psilocybe cubensis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 1
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 101710133576 Slit homolog 2 protein Proteins 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102100040391 T-complex protein 11 homolog Human genes 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- LRBUXXNEYYTLBV-UHFFFAOYSA-N n-[(2-methylphenyl)diazenyl]naphthalen-2-amine Chemical compound CC1=CC=CC=C1N=NNC1=CC=C(C=CC=C2)C2=C1 LRBUXXNEYYTLBV-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005691 oxidative coupling reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 239000002399 serotonin 2A agonist Substances 0.000 description 1
- 239000002485 serotonin 2C agonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
Definitions
- the present invention relates to compositions of psilocin and methods for providing stable compositions of psilocin as well as therapeutic indications.
- Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is a psychedelic substance found in several species of psychedelic mushrooms (Psilocybe) which cause “mind-altering” effects in humans (Hofmann et al., 1959; Nichols, 2004). Isolated in 1958 by A. Hofmann, psilocybin is a prodrug that must undergo biotransformation to the active drug psilocin. Psilocin's psychoactive effects are predominately mediated via 5-HT2A receptors (Rickli et al., 2016; Vollenweider et al., 1998).
- Psilocybin is both difficult and costly to manufacture. Shirota, et al. describe producing psilocybin from 4-hydroxyindole, which costs over $200 per gram as a starting substrate. Due to this difficulty, which is largely driven by the final manufacturing step to convert psilocin to psilocybin, scalability of the synthetic process to commercial scale is also uncertain. Other groups in Denmark have tried making psilocybin with yeast, however, while their methods eliminate the need for 4-hydroxyindole, their product yield is poor because they generate large amounts of psilocin (4-hydroxy-N,N-dimethyltryptamine), the metabolite of psilocybin.
- Psilocybin is a prodrug that requires biotransformation to psilocin mediated by alkaline phosphatases in order to have pharmacological activity. Psilocybin is both not permeable in intestinal epithelia (Eivindvik and Rasmussen, 1989) or CNS. Psilocin itself is not used in medical treatment because it is known to have poor stability due to photodegradation and oxidation in both ambient (i.e., exposed to air) and aqueous environments. Lenz, et al. (Angew. Chem. Int. Ed.
- Anastos 2006 describe improvements in psilocin sample stability when protected from light, however, there is still a 50% peak loss over 14 days which is not considered stable and is not viable for a pharmaceutical composition or drug product.
- Psilocin in biological samples (such as blood or urine) is also unstable and is degraded by both non-enzymatic and enzymatic processes (Lindenblatt 1998; Hasler 1997; Martin 2012). Improvements in psilocin stability in biological samples have been achieved by addition of 25 mM ascorbic acid, though greater than 5% of psilocin can still be lost in these samples suggesting this procedure is not sufficient to stabilize psilocin (Brown 2017; Hasler 1997).
- the present invention provides for a composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability.
- the present invention provides for a method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability.
- the present invention provides for a method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
- FIG. 1A is a table showing a study design
- FIG. 1B is a table showing a study design
- FIG. 2A is a graph showing plasma psilocin after IV dose
- FIG. 2B is a graph showing plasma psilocybin after IV dose
- FIG. 2C is a table showing values of PK characteristics
- FIG. 3A is a graph showing plasma psilocin after PO dose
- FIG. 3B is a chart showing values of PK characteristics
- FIG. 4A is a graph showing psilocin administered IV and PO
- FIG. 4B is a graph showing psilocybin administered IV and PO;
- FIG. 5 is a table showing results of the analysis of dosing solutions
- FIG. 6 shows the chemical structure of psilocin tartrate
- FIG. 7A is an OM image
- FIG. 7B is an OM image
- FIG. 7C is an OM image
- FIG. 7D is an OM image
- FIG. 7E is an OM image
- FIG. 7F is an OM image
- FIG. 8 is a graph of XPRD pattern for psilocin tartrate (initial material).
- FIG. 9 is a graph of XPRD pattern for psilocin tartrate (post DVS analysis).
- FIG. 10 is a stack plot of the patterns for psilocin tartrate (post DVS and original material).
- FIG. 11 is an annotated DSC thermogram for psilocin tartrate
- FIG. 12 is an annotated TGA curve for psilocin tartrate, with first derivative of the weight loss curve
- FIG. 13 is a graph of weight versus time for psilocin tartrate
- FIG. 14 is a graph of percent weight change versus percent relative humidity plot for psilocin tartrate
- FIG. 15 is a 1 H NMR spectrum of psilocin tartrate
- FIG. 16 is an expanded 1 H NMR spectrum of psilocin tartrate (7.6-11.5 ppm);
- FIG. 17 is an expanded 1 H NMR spectrum of psilocin tartrate (6.2-7.65 ppm);
- FIG. 18 is an expanded 1 H NMR spectrum of psilocin tartrate (0.8-5.4 ppm);
- FIG. 19 is a 1 H NMR spectrum of psilocin tartrate with integrations
- FIG. 20 is a chart showing degree of degradation of psilocin free base compared to a control
- FIG. 21 is a graph of HPLC data
- FIG. 22 is a photo showing stability of salt formations of psilocin and psilocin free base
- FIG. 23 is a graph of HPLC solution stability data
- FIG. 24 is a photo showing stability of psilocin free base (left) and psilocin tartrate salt (right);
- FIG. 25A is a graph of XRPD pattern of benzoate salt (Ben1) and FIG. 25B is a photograph showing the vacuum dried benzoate salt;
- FIG. 26A is a graph of XRPD pattern of besylate salt (Bes1) and FIG. 26B is a photograph showing the vacuum dried besylate salt;
- FIG. 27A is a graph of XRPD patterns of fumarate salts (Fum1a, Fum1b, Fum2, and Fum3)
- FIG. 27B is a photograph showing vacuum dried fumarate salt Fumla
- FIG. 27C is a photograph showing vacuum dried fumarate salt Fum1b
- FIG. 27D is a photograph showing wet fumarate salt Fum2
- FIG. 27E is a photograph showing wet fumarate salt Fum3;
- FIG. 28A is a graph of XRPD pattern of glutarate salt (Glt1)
- FIG. 28B is a photograph showing the wet glutarate salt
- FIG. 28C is a photograph showing the vacuum dried glutarate salt
- FIG. 29A is a graph of XRPD pattern of lactate salt (Lac1) and FIG. 29B is a photograph showing the vacuum dried lactate salt;
- FIG. 30A is a graph of XRPD pattern of malonate salt (Mao1) and FIG. 30B is a photograph showing the vacuum dried malonate salt;
- FIG. 31A is a graph of XRPD patterns of oxalate salts (Oxa1a to Oxa4)
- FIG. 31B is a photograph showing vacuum dried oxalate salt Oxa1a
- FIG. 31C is a photograph showing wet oxalate salt Oxa1b
- FIG. 31D is a photograph showing wet oxalate salt Oxa2a
- FIG. 31E is a photograph showing vacuum dried oxalate salt Oxa2b
- FIG. 31F is a photograph showing vacuum dried oxalate salt Oxa3
- FIG. 31G is a photograph showing vacuum dried oxalate salt Oxa4;
- FIG. 32A is a graph of XRPD pattern of phosphate salt (Pho1) and FIG. 32B is a photograph showing the vacuum dried phosphate salt;
- FIG. 33A is a graph of XPRD patterns of succinate salts (Suc1 to Suc3)
- FIG. 33B is a photograph showing the vacuum dried succinate salt Suc1
- FIG. 33C is a photograph showing the wet succinate salt Suc2
- FIG. 33D is a photograph showing the vacuum dried succinate salt Suc3;
- FIG. 34 is a graph of XRD patterns for psilocin free base, psilocin tartrate salt Form 1 (Tar1), psilocin tartrate salt Form 2 (Tar2) and three examples of amorphous psilocin tartrate salt (Am);
- FIG. 35 is an overlay comparing the XRPD pattern of psilocin tartrate salt Form 1 (Tar1) and Form 2 (Tar2);
- FIG. 36A is an XPRD graph of Tar1
- FIG. 36B is a polarized light microscopy image of crystals of Tar1;
- FIG. 37A is an XPRD graph of Tar2, and FIG. 37B is a polarized light microscopy image of crystals of Tar2;
- FIG. 38A is an XPRD graph of psilocin form A
- FIG. 38B is a polarized light microscopy image of crystals of psilocin form A;
- FIG. 39 is a representation of an asymmetric unit of psilocin tartrate crystal (Tar1);
- FIG. 40 is a Rietveld analysis on solid obtained by evaporation of a solution of psilocin tartrate Tar1 in ethanol, using the single crystal data of psilocin tartrate as a model;
- FIG. 41A is a HT-XPRD pattern of psilocin (bottom) and HBr1 (top), and FIG. 41B is an image of the material of HBr1;
- FIG. 42 is a UPLC chromatogram of HBr1
- FIG. 43 is a TGMS analysis (heating rate of 10° C./min) of HBr1;
- FIG. 44 is a DSC analysis (heating rate of 10° C./min) of HBr1;
- FIG. 45 is an overlay of 1 H-NMR spectra (DMSO-d 6 , 500 MHz) of HBr1 (bottom line), and the received batch of free base (top line).
- compositions of psilocin that are stable by various mechanisms. These compositions enable the administration of the active drug psilocin, which does not require biotransformation to be active, instead of the prodrug (psilocybin) that does not have pharmacological activity in vivo and does require biotransformation into psilocin to provide its effects.
- psilocin instead of psilocybin can provide reduced inter-subject variability in exposure to the active molecule psilocin (Hasler 1997 shows that even after IV administration of psilocybin, inter-individual variability of psilocin concentrations was over 3-fold, whereas direct psilocin administration does not result in such variability, likely due to alkaline phosphatase metabolism and glucuronidation as well as other mechanisms).
- these advantages of psilocin result in enhanced efficacy and reduced risk of side effects compared to use of psilocybin.
- “Stable” as used herein, can refer to shelf-stable (i.e., stable at ambient room temperature and humidity), as well as stable in cold storage or storage under inert conditions.
- shelf-life stability can be 3 months, 6 months, 1 year, or longer.
- the composition can include at least one agent that provides enhanced stability such as a photostabilizing agent or an antioxidant. Combinations of these agents can also be used (Anastos 2006 states that both light and air can be necessary for degradation of psilocin).
- Photostabilizing agents are used in products that can degrade during manufacturing, storage, or administration because they are sensitive to light and undergo physical or chemical changes due to light.
- Anastos 2006 has stated that a likely explanation for the degradation of psilocin or psilocybin by light is the dimerization and/or trimerization of the indoles, which is common under acidic conditions.
- protonation at C3 produces the 3H-indolium cation as the major species; this has been confirmed in solution spectroscopically.
- 3H-indolium cations are electrophilic and will react with unprotonated indole to form acid dimerisation and trimerisation products.
- the photostabilizing agent can be, but is not limited to, excipients with spectral overlay (such as Eusolex 9020 [4-(t-butyl-4′-methoxydibenzoyl)-methane], riboflavin, UV absorbers such as 3-(4-methylbenzylidene)-camphor (Eusolex 6300), or ⁇ -(o-tolylazo)- ⁇ -naphthylamine), food colorants, drug products with opacifying/coating agents (such as yellow, red, and black iron oxides incorporated in tablets, use of opaque blisters and capsules, a dye with an absorption spectrum similar to that of psilocin, use of a reflecting pigment such as titanium dioxide, addition of UV and visible absorbing opacifiers, or a film coating with agents possessing light absorption or reflection properties), or combinations thereof.
- excipients with spectral overlay such as Eusolex 9020 [4-(t-butyl-4′-methoxydi
- Antioxidants can be used to delay or inhibit oxidation of a compound by being preferentially oxidized or blocking an oxidative chain reaction.
- the antioxidant can be, but is not limited to, ascorbic acid, ⁇ -tocopherol acetate, acetone sodium bisulfite, acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride, d- ⁇ -tocopherol natural, d- ⁇ -tocopherol synthetic, dithiothreitol, monothioglycerol, nordihydroguaiaretic acid, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, thiourea, or combinations thereof.
- photostabilizing or antioxidant agents can also work synergistically with the psilocin or provide additional beneficial effects.
- prebiotics such as lactulose provide antioxidant effects as well as other advantageous effects in pain treatment.
- composition can also use chemical modifications to provide stability, such as pharmaceutical salts or polymorphs.
- Pharmaceutical salts can be formed with any cations of aluminum, arginine, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediamine, histidine, lithium, lysine, magnesium, meglumine, potassium, procaine, sodium, triethylamine, or zinc.
- Pharmaceutical salts can also be formed with any anions of acetate, aspartate, benzenesulfonate, benzoate, besylate, bicarbonate, bitartrate, bromide, camsylate, carbonate, chloride, citrate, decanoate, edetate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolate, glycollylarsanilate, hexanoate, hexylresorcinate, hydrabamine, hydroxynaphthoate, iodide, isethionate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, octanoate, oleate, pamoate, pantothenate, phosphate, polygalactur
- the composition can also be formed as an acid such as, but not limited to, naphthalene-1,5-disulfonic acid, sulfuric acid, ethane 1,2-disulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, maleic acid, phosphoric acid, ethanesulfonic, p-toluenesulfonic, methanesulfonic, glutamic, malonic, gentisic, salicylic, citric, malic (including L-malic, D-malic, and DL-malic), lactic (including L-lactic, D-lactic, and DL-lactic), benzoic, succinic, glutaric, hydrochloric, hydrobromic, oxalic, tartaric (including L-tartaric.
- an acid such as, but not limited to, naphthalene-1,5-disulfonic acid, sulfuric acid, ethane 1,2-disulfonic
- D-tartaric, and DL-tartaric fumaric, acetic, L-aspartic, galactaric, glycoloic, hippuric, gluconic, sebacic, adipic, or ascorbic (including L-ascorbic, D-ascorbic, and DL-ascorbic).
- composition can also be stored in any suitable way to prevent degradation from heat, light, air, and/or water.
- the present invention therefore provides for a method making stable psilocin, by providing a formulation of psilocin including at least one agent that provides enhanced stability.
- the composition can be in a liquid dosage form such as, but not limited to, suspensions, solutions, emulsions, elixirs, tinctures, sprays, syrups, gels, magmas, liniments, lotions, ointments, pastes, drops, or inhalants.
- the composition can be in a solid dosage form such as, but not limited to, capsules, films, lozenge, patch, powder, tablets, pellets, pills, or troches.
- composition can be administered by any route of administration, such as, but not limited to, oral, intravenous (IV) injection, intramuscular (IM) injection, subcutaneous (SC) injection, intraarterial, intraperitoneal, intratonsillar, intrathecal, infusion, intranasal, sublingual, buccal, rectal, vaginal, ocular, inhalation, nebulization, topical, transdermal, or transmucosal.
- IV intravenous
- IM intramuscular
- SC subcutaneous
- intraarterial intraperitoneal
- intratonsillar intrathecal
- infusion intranasal
- sublingual sublingual
- buccal rectal
- vaginal vaginal
- ocular ocular
- nebulization topical, transdermal, or transmucosal.
- Liposome formulations can be used with the composition, including conventional liposomes, PEGylated liposomes, ligand-targeted liposomes, and therapeutic liposomes.
- Liposomes are phospholipid vesicles of one or more concentric lipid bilayers enclosing discrete aqueous spaces that can encapsulate hydrophilic or hydrophobic drug compositions.
- Conventional liposomes include a lipid bilayer that can be composed of cationic, anionic, or neutral (phospho)lipids and cholesterol, which encloses an aqueous volume.
- PEGylated liposomes utilize polyethylene glycol (PEG) to improve liposome stability and enhance their circulation times in the blood.
- Ligand-targeted liposomes are used for site-specific delivery of drugs to designated cell types or organs in vivo, which selectively express or over-express specific ligands (e.g., receptors or cell adhesion molecules) at the site of disease.
- specific ligands e.g., receptors or cell adhesion molecules
- Nanoparticle formulations can also be used with the composition to improve the stability and solubility of the composition, promote transport across membranes, and prolong circulation times to increase safety and efficacy.
- the nanoparticle formulations can include lipid-based nanoparticles of spherical platforms including at least one lipid bilayer surrounding at least one internal aqueous compartment, which are usually made of phospholipids.
- Lipid nanoparticles can be used which are made of cationic or ionizable lipids that complex with negatively charged genetic material and aid endosomal escape, phospholipids for particle structure, cholesterol for stability and membrane fusion, and PEGylated lipids to improve stability and circulation.
- Polymeric nanoparticles can be used made from natural or synthetic materials, monomers, or preformed polymers, and the composition can be encapsulated within the core, entrapped in the polymer matrix, chemically conjugated to the polymer, or bound to the surface.
- Inorganic nanoparticles using gold, iron, or silica can be used.
- the compound of the present invention is administered and dosed in accordance with good medical practice, considering the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners.
- the pharmaceutically “effective amount” for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.
- the patient being treated is a warm-blooded animal and, in particular, mammals including man.
- the pharmaceutically acceptable carriers, diluents, adjuvants, and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.
- the doses can be single doses or multiple doses over a period of several days.
- the treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species being treated.
- the pharmaceutical formulations suitable for injection include sterile aqueous solutions, other solutions, or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- the carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Nonaqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions.
- various additives which enhance the stability, sterility, and isotonicity of the compositions including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added.
- antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
- isotonic agents for example, sugars, sodium chloride, and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.
- Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired.
- a pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres. Examples of delivery systems useful in the present invention include: U.S. Pat. Nos.
- Psilocin acts as a 5HT2A, 5HT2C, and 5HT1A agonist or partial agonist and can be administered for any condition or disease that psilocybin is administered for.
- the condition or disease can include, but is not limited to, anxiety disorders (including anxiety in advanced stage illness e.g.
- cancer as well as generalized anxiety disorder
- depression including post partum depression, major depressive disorder and treatment-resistant depression
- headache disorder including cluster headaches and migraine headache
- obsessive compulsive disorder OCD
- personality disorders including conduct disorder
- stress disorders including adjustment disorders and post-traumatic stress disorder
- drug disorders including alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence, methamphetamine dependence
- other addictions including gambling disorder, eating disorder, and body dysmorphic disorder
- pain neurodegenerative disorders (such as dementia, Alzheimer's Disease, Parkinson's Disease), autism spectrum disorder, eating disorders, or neurological disorders (such as stroke).
- the present invention provides for a method of treatment of a disease or condition, by administering a composition of psilocin that is stable, and treating the disease or condition.
- FIGS. 1A and 1B The study design is shown in FIGS. 1A and 1B .
- the study was conducted in male/female CD rats.
- Test articles were formulated fresh in PBS.
- Psilocin and Psilocybin were administered IV and PO.
- Plasma samples were analyzed for psilocin and psilocybin (group 2).
- FIGS. 2A-2C show PK characteristics of psilocin and psilocybin after IV dosing.
- FIGS. 3A-3B show PK characteristics of psilocin and psilocybin after PO dosing.
- FIGS. 4A-4B show psilocin and psilocybin after IV and PO dose.
- FIG. 5 shows dosing solution analyses.
- IV administration of psilocin (free base) and psilocybin results in almost identical PK values, including C max and AUC and Cl. After IV administration, psilocybin is detectable in plasma for 15 minutes. PO administration of psilocin and psilocybin results in similar PK values, including t max , t 1/2 , AUC, and bioavailability. Measured C max after administration of psilocybin is higher (313.7 mg/ml) compared to 152.7 ng/ml after administration of psilocin. Low stability of psilocin in aqueous solutions could be a contributing factor to observed differences.
- psilocin tartrate (lot 16782-15C) was submitted for optical microscopy (OM), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption/desorption (DVS), and 1 H NMR spectroscopy.
- OM optical microscopy
- XRPD X-ray powder diffraction
- DSC differential scanning calorimetry
- TGA thermogravimetric analysis
- DVS dynamic vapor sorption/desorption
- 1 H NMR spectroscopy The chemical structure of psilocin is displayed in FIG. 6 .
- the data in this EXAMPLE shows that psilocin tartrate is a stable crystalline solid.
- FIGS. 7A-7F show the OM images for psilocin tartrate lot 16782-15C.
- the sample contains particles that are agglomerates in various shapes.
- the agglomerates range in length from ⁇ 20 to 50 micrometers. Images of the agglomerates that were obtained with crossed polars in place show birefringence with extinction indicating that these particles are crystalline.
- the acquired XRPD patterns for psilocin tartrate, initial material, and post DVS analysis, are presented in FIGS. 8 and 9 , respectively. Based upon the observance of sharp and discrete peaks, the materials are crystalline in nature.
- a stack plot of the two XRPD patterns is presented in FIG. 10 .
- a visual comparison of the patterns shows that the patterns correspond indicating the same form or mixture of forms is in each material.
- a list of diffraction peaks for psilocin tartrate lot 16782-15C is displayed in TABLE 1.
- the annotated DSC thermogram for the psilocin tartrate lot 16782-15C is presented in FIG. 11 .
- the DSC thermogram displays an endothermic event at 161.22° C., which appears to be a melting event.
- the thermal event starting at ⁇ 180° C. is most likely decomposition as it is consistent with the rapid weight loss observed in the TGA.
- the annotated TGA curve for the psilocin tartrate lot 16782-15C is presented in FIG. 12 .
- the first derivative curve has been added to help determine the endpoint of the weight losses.
- the first minimal weight loss event, 0.76% up to 160° C., is likely related to volatile loss.
- the more rapid weight loss event from 160° C. to ⁇ 297° C. of 45.65% appears to be decomposition.
- the 1 H NMR spectrum (NMR1-1978) of psilocin tartrate lot 16782-15C is shown in FIG. 15 with expanded plots in FIGS. 16-19 .
- the 1 H chemical shift assignments for psilocin tartrate (as labeled in FIG. 6 ) were performed and indicated in each spectrum except for unidentified 1 H signals, which may be attributed to impurities in the sample.
- the samples were prepared in a silicon low background holder using light manual pressure to keep the sample surface flat and level with the reference surface of the sample holder.
- the single crystal Si low background holder has a circular recess (10 mm diameter and about 0.2 mm depth) that holds the sample.
- the Rigaku Smart-Lab diffraction system used was configured for Bragg-Brentano reflection geometry using a line source X-ray beam.
- the Bragg-Brentano geometry was controlled by passive divergence and receiving slits with the sample itself acting as the focusing component for the optics. Data collection parameters are shown in TABLE 3.
- DSC analysis was performed using a TA Instruments Discovery Series 2500 DSC instrument.
- the instrument temperature calibration was performed using indium.
- the DSC cell was kept under a nitrogen purge of ⁇ 50 mL per minute during the analysis.
- the sample was placed in a standard crimped T-zero aluminum pan covered with a lid.
- the sample was heated from ambient to 300° C. at a rate of 10° C. per minute.
- the instrument was controlled with, and software and the data were analyzed with TRIOS v. 5.0.0.44608.
- TG analysis was performed using a TA Instruments Discovery 5500 TGA instrument.
- the instrument balance was calibrated using class M weights and temperature calibration was performed by the measurement of the Curie point of Alumel® and Nickel.
- the nitrogen purge was about 10 mL per minute at the balance and about 25 mL per minute at the furnace.
- Approximately 2 mg of the sample was loaded onto tared, platinum sample pan.
- the sample was heated from ambient temperature to 300° C. at a rate of 10° C./minute.
- the instrument was controlled with, and software and the data were analyzed with TRIOS v. 5.0.0.44608.
- DVS analysis was carried out using a TA Instruments Q5000 Dynamic Vapor Sorption analyzer. The instrument was calibrated with standard weights and a sodium bromide standard for humidity. Approximately 12 mg of the powder sample was loaded into a metal-coated quartz pan for analysis. The sample was analyzed at 25° C. after being equilibrated to 5% RH in 10% RH steps from 5 to 95% RH (adsorption cycle) and from 95 to 5 % RH (desorption cycle). The movement from one step to the next occurred either after satisfying the equilibrium criterion of 0.01% weight change in 5 minutes or, if the equilibrium criterion was not met, after 90 minutes. The percent weight change values were calculated using Microsoft Excel® 2016.
- OM was conducted using a Keyence VHX-2000E digital microscope equipped with a VH-Z20R variable magnification lens assembly (20-200 ⁇ ). The sample particles were illuminated with reflected light. Photo-micrographs at high and low magnifications were acquired and processed using the VHX communication v2.35 software.
- the data shows that making a salt is a viable strategy to prepare stable psilocin solution formulations; this can be used to prepare solid psilocin formulations with enhanced shelf life and can lead to improved PK properties upon human dosing.
- the limited stability of psilocin free base under a variety of stress conditions is shown in the chart in FIG. 20 .
- HPLC data in FIG. 21 shows the improved stability of psilocin tartrate salt compared to the free base in solution.
- a salt screen using solutions in ethanol is summarized in TABLE 5. TABLE 5 shows that not all acids lead to stable salt formation under the same conditions.
- FIG. 22 was taken at an 18-hour timepoint and demonstrates visually that salt formation is effective at improving the stability of psilocin.
- a salt screen was performed on psilocin.
- the salt screen was performed according to the saturated API solution method.
- 23 counterions were explored in 3 solvent systems. For each counterion, 1.1 molar equivalent was used. In case the counterion had multiple ionization sites, 0.55 molar equivalent was also tested.
- 1M solutions of the counterion was added to (close to) saturated solution of the API in ethanol, acetonitrile, and methyl ethyl ketone.
- 1M solutions of the counterion was added to (close to) saturated solution of the API in ethanol, acetonitrile, and methyl ethyl ketone.
- ACN solutions aqueous counterion solutions were used, and with EtOH and MEK, counterion solutions prepared in THF were used.
- the mixtures were kept at RT overnight and than equilibrated at 5° C. for 3 days. Solids and liquids were separated. Solids were analyzed by XRPD wet and after drying
- FIG. 25A shows XRPD patterns of benzoate salt Ben1 compared to psilocin free base and benzoic acid.
- FIG. 25B shows the vacuum dried benzoate salt.
- FIG. 26A shows XRPD patterns of potential besylate salt Bes1 compared to psilocin free base and benzenesulfonic acid.
- FIG. 26B shows the vacuum dried besylate salt.
- FIG. 27A shows XRPD patterns of the fumarate salts compared to psilocin free base and fumaric acid.
- Fum1a and Fum1b were obtained as vacuum dry solids.
- Fum2 and Fum3 were only observed in the wet solids and converted to Fum1b upon drying
- Fum1a and Fum1b were observed in samples performed with both 1 and 0.5 molar equivalent of fumaric acid, Fum2 and Fum3 were only observed when 0.5 molar equivalent of fumaric acid was used.
- FIGS. 27B-27E show the different fumarate salts.
- FIG. 28A shows XRPD patterns of glutarate salt Glt1 compared to psilocin free base and glutaric acid.
- FIG. 28B shows the wet glutarate salt and
- FIG. 28C shows vacuum dried glutarate salt.
- FIG. 29A shows XRPD patterns of lactate salt Lac1 compared to psilocin free base and lactic acid.
- FIG. 29B shows the vacuum dried lactate salt.
- FIG. 30A shows XRPD patterns of potential malonate salt Mao1 compared to psilocin free base and malonic acid.
- FIG. 30B shows the vacuum dried malonate salt.
- FIG. 31A shows XRPD patterns of the oxalate salts compared to psilocin free base and oxalic acid.
- Oxa1a and Oxa1b were obtained from experiments performed with 1 molar equivalent oxalic acid, while the other oxalate salts were obtained from experiments with 0.5 molar equivalent.
- FIGS. 31B-31G show the different oxalate salts.
- FIG. 32A shows XRPD patterns of phosphate salt Pho1 compared to psilocin free base.
- FIG. 32B shows the vacuum dried phosphate salt.
- FIG. 33A shows XRPD patterns of succinate salts compared to psilocin free base and succinic acid.
- Suc1 was obtained from the experiments performed in MEK (both ratios), and Suc2 was obtained from the experiment performed with 0.5 molar equivalent succinic acid in ACN and converted to Suc3 upon drying.
- FIGS. 33B-33D show the different succinate salts.
- FIG. 34 shows a comparison of the XRD patterns for psilocin free base, psilocin tartrate salt Form 1 (Tar1), psilocin tartrate salt Form 2 (Tar2) and three examples of amorphous psilocin tartrate salt (Am).
- 20 mg of API and 15 mg of tartaric acid were weighed in vials (molar ratio 1:1). Aliquots of 100 ⁇ L solvent were added until the solids were dissolved. The obtained solutions were frozen in liquid nitrogen and placed in the freeze dryer overnight. From water, water/THF 50/50 and water/dioxane 50/50 amorphous solids were recovered.
- the solid from water contained 1.3% residual water, while the solids obtained from the THF and dioxane mixtures contained 7.8 and 10.3% solvent, respectively.
- the solid obtained from the acetonitrile mixture was crystalline and had a different XRPD than the free base or the already known tartrate salt and was designated Tar2. All solids had a purity of about 99%.
- the material to be used for polymorph screening was prepared by freeze drying a solution in water.
- FIG. 35 is an overlay comparing the XRPD pattern of psilocin tartrate salt Form 1 (Tar1) and Form 2 (Tar2).
- TCP13 was isolated from acetone/water, 95:5 as follows. To about 35 mg of amorphous psilocin tartrate salt, acetone/water (95:5) was added in small aliquots until a thin suspension was obtained. The suspension was subjected to a temperature cycling profile, of 3 cycles between 5 and 50° C. with a heating rate of 10° C./h and cooling rates of 20, 10 and 5° C./h, with a final aging stage at 25° C. for 48 hours. The solids were isolated and analyzed by XRPD after drying at ambient conditions and under vacuum at 50 C. The gently dried and harshly dried solids had the same XRPD patterns.
- TABLE 7 shows high throughput XRPD peak information for Tar1 and TABLE 8 shows high throughput XRPD peak information for Tar2.
- XRPD peak information from high resolution XRPD may vary from that presented in these tables.
- FIG. 36A shows an XPRD graph of Whole Powder Pattern Decomposition analysis of the tartrate salt Tar1.
- the refinement data and cell parameters are shown in TABLE 9.
- FIG. 36B shows the polarized light microscopy image taken with 20 ⁇ magnification.
- the solid consists of small needle like crystals with longest size close to 0.05 mm that are arranged in aggregates looking like hay sheaves.
- FIG. 37A shows an XPRD graph of Whole Powder Pattern Decomposition analysis of the tartrate salt Tar2.
- the refinement data and cell parameters are shown in TABLE 11.
- FIG. 37B shows the polarized light microscopy image taken with 10 ⁇ magnification.
- the solid consists of small needle like crystals with longest size close to 0.05 mm that are arranged in aggregates looking like hay sheaves.
- FIG. 38A Rietveld analysis of psilocin as received, using CCDC 1238288 single crystal data as a model is shown in FIG. 38A .
- FIG. 38B shows the polarized light microscopy image taken with 20 ⁇ magnification.
- the solid consists of plate like crystals with the longest sizes close to 0.05 mm.
- FIG. 39 shows an asymmetric unit of psilocin tartrate crystal (Tar1), with the hydrogen bond shown between the two molecules.
- the charged N3 atom interacts in bifurcated hydrogen bonds. One interaction is directed toward the carboxylic non deprotonated acidic group, while the second interaction is directed toward the (deprotonated) acidic carboxylate group.
- the N—H group from the fused ring act as H-bond donor to the hydroxyl group of the anion closer to the carboxylate (O27) as acceptor.
- the crystal is built up by an extensive hydrogen bonds network, where each N or O connected H atom is utilized as donor of hydrogen bonds, while every O atom serves as hydrogen bonds acceptor. TABLE 15 shows crystallographic parameters.
- a HR-XRPD pattern was collected using the crushed crystals that were obtained by evaporation from ethanol. Comparison of this HR-XRPD pattern with the simulated XRPD from the single crystal data confirmed that the patterns were identical. Rietveld analysis was performed on the HR-XRPD data, using the single crystal data as model. No crystalline impurities were detected ( FIG. 40 , TABLE 16). The top lines represent collected data and calculated and the bottom line is the difference between them. The sticks at the bottom show the peak positions of the unit cell.
- FIG. 41A Evaporation of the mother liquor of a salt screen experiment performed with 1.1 molar equivalent of hydrobromic acid in MEK resulted in the recovery of HBr1.
- the HT-XRPD pattern of the solid are shown in FIG. 41A .
- HBr1 was unstable upon exposure to AAC for two days and became deliquescent.
- FIG. 41B shows an image of the material of HBr1.
- the TGMS analysis of HBr1 ( FIG. 43 ) showed a mass loss of 4.7% in the range 25-180° C., which could correspond to 0.20 MEK molecules per API salt unit.
- the DSC trace of HBr1 ( FIG. 44 ) showed two endothermic events at 88.1° C. and at 145.6° C., possibly related to the mass loss observed by TGMS analysis and melting, respectively.
- the 1 H-NMR spectrum of HBr1 is shown in FIG. 45 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to compositions of psilocin and methods for providing stable compositions of psilocin as well as therapeutic indications.
- Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is a psychedelic substance found in several species of psychedelic mushrooms (Psilocybe) which cause “mind-altering” effects in humans (Hofmann et al., 1959; Nichols, 2004). Isolated in 1958 by A. Hofmann, psilocybin is a prodrug that must undergo biotransformation to the active drug psilocin. Psilocin's psychoactive effects are predominately mediated via 5-HT2A receptors (Rickli et al., 2016; Vollenweider et al., 1998). Recently, psilocybin has been repurposed and investigated for the treatment of cluster headache, obsessive compulsive disorder, anxiety and depression, and in alcohol use disorder (Bogenschutz et al., 2018; Carhart-Harris et al., 2017; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2017; Moreno et al., 2006; Ross et al., 2016; Sewell et al., 2006).
- Psilocybin is both difficult and costly to manufacture. Shirota, et al. describe producing psilocybin from 4-hydroxyindole, which costs over $200 per gram as a starting substrate. Due to this difficulty, which is largely driven by the final manufacturing step to convert psilocin to psilocybin, scalability of the synthetic process to commercial scale is also uncertain. Other groups in Denmark have tried making psilocybin with yeast, however, while their methods eliminate the need for 4-hydroxyindole, their product yield is poor because they generate large amounts of psilocin (4-hydroxy-N,N-dimethyltryptamine), the metabolite of psilocybin.
- Psilocybin is a prodrug that requires biotransformation to psilocin mediated by alkaline phosphatases in order to have pharmacological activity. Psilocybin is both not permeable in intestinal epithelia (Eivindvik and Rasmussen, 1989) or CNS. Psilocin itself is not used in medical treatment because it is known to have poor stability due to photodegradation and oxidation in both ambient (i.e., exposed to air) and aqueous environments. Lenz, et al. (Angew. Chem. Int. Ed. 2020, 59, 1450-1454) report that upon injury, psychotropic psilocybin-producing mushrooms instantly develop an intense blue color and two enzymes from Psilocybe cubensis carry out a two-step cascade to prepare psilocybin for oxidative oligomerization that leads to blue products. The phosphatase PsiP removes the 4-O-phosphate group to yield psilocin, while PsiL oxidizes its 4-hydroxy group. The PsiL reaction was monitored by in situ 13C NMR spectroscopy, which indicated that oxidative coupling of psilocyl residues occurs primarily via C-5. MS and IR spectroscopy indicated the formation of a heterogeneous mixture of preferentially psilocyl 3- to 13-mers and suggest multiple oligomerization routes, depending on oxidative power and substrate concentration.
- Anastos 2006 describe improvements in psilocin sample stability when protected from light, however, there is still a 50% peak loss over 14 days which is not considered stable and is not viable for a pharmaceutical composition or drug product. Psilocin in biological samples (such as blood or urine) is also unstable and is degraded by both non-enzymatic and enzymatic processes (Lindenblatt 1998; Hasler 1997; Martin 2012). Improvements in psilocin stability in biological samples have been achieved by addition of 25 mM ascorbic acid, though greater than 5% of psilocin can still be lost in these samples suggesting this procedure is not sufficient to stabilize psilocin (Brown 2017; Hasler 1997). Others have tried to find other stable versions of psilocin, such as by synthesizing psilocin glucuronide which provides a greater long-term stability after six months in in deep frozen serum and urine samples than psilocin, and a short-term stability for one week in whole blood at room temperature and in deep frozen samples better than that of psilocin (Martin et al., 2014). Psilocin glucuronide is not suitable as a drug formulation as it is unlikely to be able to permeate the blood-brain barrier and is likely to be rapidly eliminated in urine.
- As a result of the required biotransformation of psilocybin to psilocin, the pharmacokinetics of psilocin are highly variable following administration of psilocybin by multiple routes of administration. In fact, even following intravenous administration of psilocybin, maximum plasma concentrations of psilocin can vary over three-fold between individuals, resulting in an increased risk of adverse effects or inability to achieve efficacious concentrations (Hasler et al., 1997).
- Others have sought to stabilize psilocin in biological samples (i.e., plasma, urine) to enhance the stability of these samples prior to analysis through the addition of ascorbic acid, freeze drying and use of ultracold storage conditions (Brown et al., 2017; Hasler et al., 1997; Martin et al., 2012); however, these attempts were only partially successful at stabilizing psilocin in biological samples with psilocin continuing to demonstrate significant instability in biological samples. No prior art exists disclosing an attempt to stabilize psilocin in a pharmaceutical formulation for administration to humans or other animals.
- There remains a need for methods of increasing the stability of psilocin and using psilocin in treatments as a more efficacious, cost effective, and robust therapeutic, especially for neurological, psychological, substance use and pain disorders.
- The present invention provides for a composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability.
- The present invention provides for a method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability.
- The present invention provides for a method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
- Other advantages of the present invention are readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
-
FIG. 1A is a table showing a study design, andFIG. 1B is a table showing a study design; -
FIG. 2A is a graph showing plasma psilocin after IV dose,FIG. 2B is a graph showing plasma psilocybin after IV dose, andFIG. 2C is a table showing values of PK characteristics; -
FIG. 3A is a graph showing plasma psilocin after PO dose, andFIG. 3B is a chart showing values of PK characteristics; -
FIG. 4A is a graph showing psilocin administered IV and PO, andFIG. 4B is a graph showing psilocybin administered IV and PO; -
FIG. 5 is a table showing results of the analysis of dosing solutions; -
FIG. 6 shows the chemical structure of psilocin tartrate; -
FIG. 7A is an OM image,FIG. 7B is an OM image,FIG. 7C is an OM image,FIG. 7D is an OM image,FIG. 7E is an OM image,FIG. 7F is an OM image; -
FIG. 8 is a graph of XPRD pattern for psilocin tartrate (initial material); -
FIG. 9 is a graph of XPRD pattern for psilocin tartrate (post DVS analysis); -
FIG. 10 is a stack plot of the patterns for psilocin tartrate (post DVS and original material); -
FIG. 11 is an annotated DSC thermogram for psilocin tartrate; -
FIG. 12 is an annotated TGA curve for psilocin tartrate, with first derivative of the weight loss curve; -
FIG. 13 is a graph of weight versus time for psilocin tartrate; -
FIG. 14 is a graph of percent weight change versus percent relative humidity plot for psilocin tartrate; -
FIG. 15 is a 1H NMR spectrum of psilocin tartrate; -
FIG. 16 is an expanded 1H NMR spectrum of psilocin tartrate (7.6-11.5 ppm); -
FIG. 17 is an expanded 1H NMR spectrum of psilocin tartrate (6.2-7.65 ppm); -
FIG. 18 is an expanded 1H NMR spectrum of psilocin tartrate (0.8-5.4 ppm); -
FIG. 19 is a 1H NMR spectrum of psilocin tartrate with integrations; -
FIG. 20 is a chart showing degree of degradation of psilocin free base compared to a control; -
FIG. 21 is a graph of HPLC data; -
FIG. 22 is a photo showing stability of salt formations of psilocin and psilocin free base; -
FIG. 23 is a graph of HPLC solution stability data; -
FIG. 24 is a photo showing stability of psilocin free base (left) and psilocin tartrate salt (right); -
FIG. 25A is a graph of XRPD pattern of benzoate salt (Ben1) andFIG. 25B is a photograph showing the vacuum dried benzoate salt; -
FIG. 26A is a graph of XRPD pattern of besylate salt (Bes1) andFIG. 26B is a photograph showing the vacuum dried besylate salt; -
FIG. 27A is a graph of XRPD patterns of fumarate salts (Fum1a, Fum1b, Fum2, and Fum3),FIG. 27B is a photograph showing vacuum dried fumarate salt Fumla,FIG. 27C is a photograph showing vacuum dried fumarate salt Fum1b,FIG. 27D is a photograph showing wet fumarate salt Fum2, andFIG. 27E is a photograph showing wet fumarate salt Fum3; -
FIG. 28A is a graph of XRPD pattern of glutarate salt (Glt1),FIG. 28B is a photograph showing the wet glutarate salt, andFIG. 28C is a photograph showing the vacuum dried glutarate salt; -
FIG. 29A is a graph of XRPD pattern of lactate salt (Lac1) andFIG. 29B is a photograph showing the vacuum dried lactate salt; -
FIG. 30A is a graph of XRPD pattern of malonate salt (Mao1) andFIG. 30B is a photograph showing the vacuum dried malonate salt; -
FIG. 31A is a graph of XRPD patterns of oxalate salts (Oxa1a to Oxa4),FIG. 31B is a photograph showing vacuum dried oxalate salt Oxa1a,FIG. 31C is a photograph showing wet oxalate salt Oxa1b,FIG. 31D is a photograph showing wet oxalate salt Oxa2a,FIG. 31E is a photograph showing vacuum dried oxalate salt Oxa2b,FIG. 31F is a photograph showing vacuum dried oxalate salt Oxa3, andFIG. 31G is a photograph showing vacuum dried oxalate salt Oxa4; -
FIG. 32A is a graph of XRPD pattern of phosphate salt (Pho1) andFIG. 32B is a photograph showing the vacuum dried phosphate salt; -
FIG. 33A is a graph of XPRD patterns of succinate salts (Suc1 to Suc3),FIG. 33B is a photograph showing the vacuum dried succinate salt Suc1,FIG. 33C is a photograph showing the wet succinate salt Suc2, andFIG. 33D is a photograph showing the vacuum dried succinate salt Suc3; -
FIG. 34 is a graph of XRD patterns for psilocin free base, psilocin tartrate salt Form 1 (Tar1), psilocin tartrate salt Form 2 (Tar2) and three examples of amorphous psilocin tartrate salt (Am); -
FIG. 35 is an overlay comparing the XRPD pattern of psilocin tartrate salt Form 1 (Tar1) and Form 2 (Tar2); -
FIG. 36A is an XPRD graph of Tar1, andFIG. 36B is a polarized light microscopy image of crystals of Tar1; -
FIG. 37A is an XPRD graph of Tar2, andFIG. 37B is a polarized light microscopy image of crystals of Tar2; -
FIG. 38A is an XPRD graph of psilocin form A, andFIG. 38B is a polarized light microscopy image of crystals of psilocin form A; -
FIG. 39 is a representation of an asymmetric unit of psilocin tartrate crystal (Tar1); -
FIG. 40 is a Rietveld analysis on solid obtained by evaporation of a solution of psilocin tartrate Tar1 in ethanol, using the single crystal data of psilocin tartrate as a model; -
FIG. 41A is a HT-XPRD pattern of psilocin (bottom) and HBr1 (top), andFIG. 41B is an image of the material of HBr1; -
FIG. 42 is a UPLC chromatogram of HBr1; -
FIG. 43 is a TGMS analysis (heating rate of 10° C./min) of HBr1; -
FIG. 44 is a DSC analysis (heating rate of 10° C./min) of HBr1; and -
FIG. 45 is an overlay of 1H-NMR spectra (DMSO-d6, 500 MHz) of HBr1 (bottom line), and the received batch of free base (top line). - The present invention provides for compositions of psilocin that are stable by various mechanisms. These compositions enable the administration of the active drug psilocin, which does not require biotransformation to be active, instead of the prodrug (psilocybin) that does not have pharmacological activity in vivo and does require biotransformation into psilocin to provide its effects. Use of psilocin instead of psilocybin can provide reduced inter-subject variability in exposure to the active molecule psilocin (Hasler 1997 shows that even after IV administration of psilocybin, inter-individual variability of psilocin concentrations was over 3-fold, whereas direct psilocin administration does not result in such variability, likely due to alkaline phosphatase metabolism and glucuronidation as well as other mechanisms). Ultimately, these advantages of psilocin result in enhanced efficacy and reduced risk of side effects compared to use of psilocybin.
- “Stable” as used herein, can refer to shelf-stable (i.e., stable at ambient room temperature and humidity), as well as stable in cold storage or storage under inert conditions. For example, shelf-life stability can be 3 months, 6 months, 1 year, or longer.
- The composition can include at least one agent that provides enhanced stability such as a photostabilizing agent or an antioxidant. Combinations of these agents can also be used (Anastos 2006 states that both light and air can be necessary for degradation of psilocin).
- Photostabilizing agents are used in products that can degrade during manufacturing, storage, or administration because they are sensitive to light and undergo physical or chemical changes due to light. Anastos 2006 has stated that a likely explanation for the degradation of psilocin or psilocybin by light is the dimerization and/or trimerization of the indoles, which is common under acidic conditions. For indoles under acidic conditions, protonation at C3 produces the 3H-indolium cation as the major species; this has been confirmed in solution spectroscopically. 3H-indolium cations are electrophilic and will react with unprotonated indole to form acid dimerisation and trimerisation products. The photostabilizing agent can be, but is not limited to, excipients with spectral overlay (such as Eusolex 9020 [4-(t-butyl-4′-methoxydibenzoyl)-methane], riboflavin, UV absorbers such as 3-(4-methylbenzylidene)-camphor (Eusolex 6300), or α-(o-tolylazo)-β-naphthylamine), food colorants, drug products with opacifying/coating agents (such as yellow, red, and black iron oxides incorporated in tablets, use of opaque blisters and capsules, a dye with an absorption spectrum similar to that of psilocin, use of a reflecting pigment such as titanium dioxide, addition of UV and visible absorbing opacifiers, or a film coating with agents possessing light absorption or reflection properties), or combinations thereof.
- Antioxidants can be used to delay or inhibit oxidation of a compound by being preferentially oxidized or blocking an oxidative chain reaction. The antioxidant can be, but is not limited to, ascorbic acid, α-tocopherol acetate, acetone sodium bisulfite, acetylcysteine, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride, d-α-tocopherol natural, d-α-tocopherol synthetic, dithiothreitol, monothioglycerol, nordihydroguaiaretic acid, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, thiourea, or combinations thereof.
- Any of the photostabilizing or antioxidant agents can also work synergistically with the psilocin or provide additional beneficial effects. For example, prebiotics such as lactulose provide antioxidant effects as well as other advantageous effects in pain treatment.
- The composition can also use chemical modifications to provide stability, such as pharmaceutical salts or polymorphs. Pharmaceutical salts can be formed with any cations of aluminum, arginine, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediamine, histidine, lithium, lysine, magnesium, meglumine, potassium, procaine, sodium, triethylamine, or zinc. Pharmaceutical salts can also be formed with any anions of acetate, aspartate, benzenesulfonate, benzoate, besylate, bicarbonate, bitartrate, bromide, camsylate, carbonate, chloride, citrate, decanoate, edetate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolate, glycollylarsanilate, hexanoate, hexylresorcinate, hydrabamine, hydroxynaphthoate, iodide, isethionate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, octanoate, oleate, pamoate, pantothenate, phosphate, polygalacturonate, propionate, salicylate, stearate, subacetate, succinate, sulfate, tartrate, teoclate, tosylate, or triethiodide. Deuterated psilocin can be used to provide stability in which one or more hydrogen atoms in psilocin have been replaced with deuterium atoms.
- The composition can also be formed as an acid such as, but not limited to, naphthalene-1,5-disulfonic acid, sulfuric acid,
ethane 1,2-disulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, maleic acid, phosphoric acid, ethanesulfonic, p-toluenesulfonic, methanesulfonic, glutamic, malonic, gentisic, salicylic, citric, malic (including L-malic, D-malic, and DL-malic), lactic (including L-lactic, D-lactic, and DL-lactic), benzoic, succinic, glutaric, hydrochloric, hydrobromic, oxalic, tartaric (including L-tartaric. D-tartaric, and DL-tartaric), fumaric, acetic, L-aspartic, galactaric, glycoloic, hippuric, gluconic, sebacic, adipic, or ascorbic (including L-ascorbic, D-ascorbic, and DL-ascorbic). - The composition can also be stored in any suitable way to prevent degradation from heat, light, air, and/or water.
- The present invention therefore provides for a method making stable psilocin, by providing a formulation of psilocin including at least one agent that provides enhanced stability.
- The composition can be in a liquid dosage form such as, but not limited to, suspensions, solutions, emulsions, elixirs, tinctures, sprays, syrups, gels, magmas, liniments, lotions, ointments, pastes, drops, or inhalants. The composition can be in a solid dosage form such as, but not limited to, capsules, films, lozenge, patch, powder, tablets, pellets, pills, or troches.
- The composition can be administered by any route of administration, such as, but not limited to, oral, intravenous (IV) injection, intramuscular (IM) injection, subcutaneous (SC) injection, intraarterial, intraperitoneal, intratonsillar, intrathecal, infusion, intranasal, sublingual, buccal, rectal, vaginal, ocular, inhalation, nebulization, topical, transdermal, or transmucosal.
- Liposome formulations can be used with the composition, including conventional liposomes, PEGylated liposomes, ligand-targeted liposomes, and therapeutic liposomes. Liposomes are phospholipid vesicles of one or more concentric lipid bilayers enclosing discrete aqueous spaces that can encapsulate hydrophilic or hydrophobic drug compositions. Conventional liposomes include a lipid bilayer that can be composed of cationic, anionic, or neutral (phospho)lipids and cholesterol, which encloses an aqueous volume. PEGylated liposomes utilize polyethylene glycol (PEG) to improve liposome stability and enhance their circulation times in the blood. Ligand-targeted liposomes are used for site-specific delivery of drugs to designated cell types or organs in vivo, which selectively express or over-express specific ligands (e.g., receptors or cell adhesion molecules) at the site of disease.
- Nanoparticle formulations can also be used with the composition to improve the stability and solubility of the composition, promote transport across membranes, and prolong circulation times to increase safety and efficacy. The nanoparticle formulations can include lipid-based nanoparticles of spherical platforms including at least one lipid bilayer surrounding at least one internal aqueous compartment, which are usually made of phospholipids. Lipid nanoparticles can be used which are made of cationic or ionizable lipids that complex with negatively charged genetic material and aid endosomal escape, phospholipids for particle structure, cholesterol for stability and membrane fusion, and PEGylated lipids to improve stability and circulation. Polymeric nanoparticles (including nanocapsules and nanospheres) can be used made from natural or synthetic materials, monomers, or preformed polymers, and the composition can be encapsulated within the core, entrapped in the polymer matrix, chemically conjugated to the polymer, or bound to the surface. Inorganic nanoparticles using gold, iron, or silica can be used.
- The compound of the present invention is administered and dosed in accordance with good medical practice, considering the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically “effective amount” for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.
- The patient being treated is a warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, diluents, adjuvants, and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.
- The doses can be single doses or multiple doses over a period of several days. The treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species being treated.
- When administering the compound of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical formulations suitable for injection include sterile aqueous solutions, other solutions, or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Nonaqueous vehicles such a cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions. Additionally, various additives which enhance the stability, sterility, and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.
- Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired.
- A pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres. Examples of delivery systems useful in the present invention include: U.S. Pat. Nos. 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. Many other such implants, delivery systems, and modules are well known to those skilled in the art.
- Psilocin acts as a 5HT2A, 5HT2C, and 5HT1A agonist or partial agonist and can be administered for any condition or disease that psilocybin is administered for. The condition or disease can include, but is not limited to, anxiety disorders (including anxiety in advanced stage illness e.g. cancer, as well as generalized anxiety disorder), depression (including post partum depression, major depressive disorder and treatment-resistant depression), headache disorder (including cluster headaches and migraine headache), obsessive compulsive disorder (OCD), personality disorders (including conduct disorder), stress disorders (including adjustment disorders and post-traumatic stress disorder), drug disorders (including alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence, methamphetamine dependence), other addictions (including gambling disorder, eating disorder, and body dysmorphic disorder), pain, neurodegenerative disorders (such as dementia, Alzheimer's Disease, Parkinson's Disease), autism spectrum disorder, eating disorders, or neurological disorders (such as stroke).
- Therefore, the present invention provides for a method of treatment of a disease or condition, by administering a composition of psilocin that is stable, and treating the disease or condition.
- The invention is further described in detail by reference to the following experimental examples. These examples are provided for the purpose of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
- The study design is shown in
FIGS. 1A and 1B . The study was conducted in male/female CD rats. Test articles were formulated fresh in PBS. Psilocin and Psilocybin were administered IV and PO. Plasma samples were analyzed for psilocin and psilocybin (group 2). -
FIGS. 2A-2C show PK characteristics of psilocin and psilocybin after IV dosing.FIGS. 3A-3B show PK characteristics of psilocin and psilocybin after PO dosing.FIGS. 4A-4B show psilocin and psilocybin after IV and PO dose.FIG. 5 shows dosing solution analyses. - IV administration of psilocin (free base) and psilocybin results in almost identical PK values, including Cmax and AUC and Cl. After IV administration, psilocybin is detectable in plasma for 15 minutes. PO administration of psilocin and psilocybin results in similar PK values, including tmax, t1/2, AUC, and bioavailability. Measured Cmax after administration of psilocybin is higher (313.7 mg/ml) compared to 152.7 ng/ml after administration of psilocin. Low stability of psilocin in aqueous solutions could be a contributing factor to observed differences. Analytical characterization of dosing solutions used in the PK study, after 2 hours on the bench at room temperature demonstrates that psilocin solutions have approximately 30%-70% degradation, depending on the concentration. Stabilization of psilocin provides viable, stable formulations and lower variability of dosing solutions, resulting in a better PK, such as compared to psilocybin.
- One sample of psilocin tartrate (lot 16782-15C) was submitted for optical microscopy (OM), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption/desorption (DVS), and 1H NMR spectroscopy. The chemical structure of psilocin is displayed in
FIG. 6 . The data in this EXAMPLE shows that psilocin tartrate is a stable crystalline solid. -
FIGS. 7A-7F show the OM images for psilocin tartrate lot 16782-15C. The sample contains particles that are agglomerates in various shapes. The agglomerates range in length from ˜20 to 50 micrometers. Images of the agglomerates that were obtained with crossed polars in place show birefringence with extinction indicating that these particles are crystalline. - The acquired XRPD patterns for psilocin tartrate, initial material, and post DVS analysis, are presented in
FIGS. 8 and 9 , respectively. Based upon the observance of sharp and discrete peaks, the materials are crystalline in nature. A stack plot of the two XRPD patterns is presented inFIG. 10 . A visual comparison of the patterns shows that the patterns correspond indicating the same form or mixture of forms is in each material. A list of diffraction peaks for psilocin tartrate lot 16782-15C is displayed in TABLE 1. -
TABLE 1 XRPD Peak List for Psilocin Tartrate Lot 16782-15C Peak Position Height Relative No. (°2θ) (cps) Height 1 6.6713 437 2.24 2 11.2219 144 0.74 3 12.6191 1068 5.48 4 13.3782 2592 13.31 5 14.6880 4173 21.43 6 15.8348 1984 10.19 7 16.2121 882 4.53 8 17.2119 19472 100.00 9 18.7798 8512 43.71 10 19.9341 7290 37.44 11 20.1303 6674 34.27 12 20.7831 2425 12.46 13 21.7831 7093 36.43 14 22.5575 11129 57.15 15 23.4041 2576 13.23 16 23.6627 2544 13.07 17 24.5334 2529 12.99 18 24.7431 3746 19.24 19 25.4678 2480 12.73 20 26.5473 2549 13.09 21 26.9630 1098 5.64 22 27.3972 464 2.38 23 28.0135 506 2.60 24 28.4814 2352 12.08 25 28.9430 789 4.05 26 29.1422 1062 5.46 27 29.4225 1512 7.77 28 30.9344 1601 8.22 29 31.4133 968 4.97 30 31.9523 769 3.95 31 32.1452 918 4.71 32 33.0004 433 2.22 33 33.9094 523 2.69 34 34.2194 1564 8.03 35 34.7791 583 2.99 36 35.1879 672 3.45 37 36.1506 841 4.32 38 37.3310 2076 10.66 39 37.6760 1037 5.33 40 38.5589 1192 6.12 - The annotated DSC thermogram for the psilocin tartrate lot 16782-15C is presented in
FIG. 11 . The DSC thermogram displays an endothermic event at 161.22° C., which appears to be a melting event. The thermal event starting at ˜180° C. is most likely decomposition as it is consistent with the rapid weight loss observed in the TGA. - The annotated TGA curve for the psilocin tartrate lot 16782-15C is presented in
FIG. 12 . The first derivative curve has been added to help determine the endpoint of the weight losses. The first minimal weight loss event, 0.76% up to 160° C., is likely related to volatile loss. The more rapid weight loss event from 160° C. to ˜297° C. of 45.65% appears to be decomposition. - The weight versus time and percent weight change versus percent relative humidity (RH) curves from the DVS analysis of psilocin tartrate lot 16782-15C is presented in
FIGS. 13 and 14 , respectively. The data show that the sample takes up water suggesting that the sample is moderately hygroscopic and exhibited some hysteresis between the 80-95% RH range. The results are listed in TABLE 2. -
TABLE 2 Summary of DVS Results Lot Number DVS Results 16782-15C 0.12% wt. loss upon equilibration at 5% RH 4.64% wt. gain from 5 to 95% RH 4.67% wt. loss from 95 to 5% RH - The 1H NMR spectrum (NMR1-1978) of psilocin tartrate lot 16782-15C is shown in
FIG. 15 with expanded plots inFIGS. 16-19 . The 1H chemical shift assignments for psilocin tartrate (as labeled inFIG. 6 ) were performed and indicated in each spectrum except for unidentified 1H signals, which may be attributed to impurities in the sample. - The samples were prepared in a silicon low background holder using light manual pressure to keep the sample surface flat and level with the reference surface of the sample holder. The single crystal Si low background holder has a circular recess (10 mm diameter and about 0.2 mm depth) that holds the sample.
- The Rigaku Smart-Lab diffraction system used was configured for Bragg-Brentano reflection geometry using a line source X-ray beam. The Bragg-Brentano geometry was controlled by passive divergence and receiving slits with the sample itself acting as the focusing component for the optics. Data collection parameters are shown in TABLE 3.
-
TABLE 3 Data Collection Parameters Parameter Value Parameter Value Geometry Bragg- Brentano Receiving 18 Slit 1 (mm) Tube Anode Cu Kα Receiving open Slit 2 (mm) Tube Type Long Fine Focus Start Angle 2 (°2θ) Tube Voltage (kV) 40 End Angle 40 (°2θ) Tube Current (mA) 44 Step Size 0.02 (°2θ) Detector D/ teX Ultra 250Scan Speed 6 (°2θ/min) Monochromatization Kβ Filter Spinning (rpm) 11 Incident Slit (°) 1/3 Sample Holder Large well silicon low background holder - DSC analysis was performed using a TA Instruments Discovery Series 2500 DSC instrument. The instrument temperature calibration was performed using indium. The DSC cell was kept under a nitrogen purge of ˜50 mL per minute during the analysis. The sample was placed in a standard crimped T-zero aluminum pan covered with a lid. The sample was heated from ambient to 300° C. at a rate of 10° C. per minute. The instrument was controlled with, and software and the data were analyzed with TRIOS v. 5.0.0.44608.
- TG analysis was performed using a TA Instruments Discovery 5500 TGA instrument. The instrument balance was calibrated using class M weights and temperature calibration was performed by the measurement of the Curie point of Alumel® and Nickel. The nitrogen purge was about 10 mL per minute at the balance and about 25 mL per minute at the furnace. Approximately 2 mg of the sample was loaded onto tared, platinum sample pan. During analysis, the sample was heated from ambient temperature to 300° C. at a rate of 10° C./minute. The instrument was controlled with, and software and the data were analyzed with TRIOS v. 5.0.0.44608.
- DVS analysis was carried out using a TA Instruments Q5000 Dynamic Vapor Sorption analyzer. The instrument was calibrated with standard weights and a sodium bromide standard for humidity. Approximately 12 mg of the powder sample was loaded into a metal-coated quartz pan for analysis. The sample was analyzed at 25° C. after being equilibrated to 5% RH in 10% RH steps from 5 to 95% RH (adsorption cycle) and from 95 to 5 % RH (desorption cycle). The movement from one step to the next occurred either after satisfying the equilibrium criterion of 0.01% weight change in 5 minutes or, if the equilibrium criterion was not met, after 90 minutes. The percent weight change values were calculated using Microsoft Excel® 2016.
- OM was conducted using a Keyence VHX-2000E digital microscope equipped with a VH-Z20R variable magnification lens assembly (20-200×). The sample particles were illuminated with reflected light. Photo-micrographs at high and low magnifications were acquired and processed using the VHX communication v2.35 software.
- The 1H NMR spectrum was acquired on a
Bruker NEO 400 MHz (9.4 T) spectrometer using TopSpin v4.1.1 software. Psilocin tartrate (3.2 mg) was dissolved in 0.75 mL of DMSO-d6, transferred into a 5-mm NMR tube for subsequent data acquisition. Each spectrum was processed using TopSpin v4.1.1 and referenced to the chemical shift of the residual DMSO-d6 (2.5 ppm). Detailed acquisition parameters are listed in TABLE 4. -
TABLE 4 NMR Acquisition Parameters Parameter Name Parameter Value Transmitter Frequency 400.15 MHz Acquisition Time 2.5 sec Spectral Width 6250 Hz Number of Scans 32 Sequence ZG30 P1 (pulse width) 12.8 μsec PLW1 (pulse power) 13.7 W D1 (relaxation delay) 4 set Line Broadening 0.5 Hz - In this EXAMPLE, the data shows that making a salt is a viable strategy to prepare stable psilocin solution formulations; this can be used to prepare solid psilocin formulations with enhanced shelf life and can lead to improved PK properties upon human dosing. The limited stability of psilocin free base under a variety of stress conditions is shown in the chart in
FIG. 20 . HPLC data inFIG. 21 shows the improved stability of psilocin tartrate salt compared to the free base in solution. A salt screen using solutions in ethanol is summarized in TABLE 5. TABLE 5 shows that not all acids lead to stable salt formation under the same conditions. -
TABLE 5 Vial # Acid Results at 18 ha,b Result at 6 days 1 Adipic V ↑ C 2 Ascorbic 0 C + solid 3 t- Cinnamic P NC 4 Fumaric F c 0 + X 5 Glycolic F c ↑ C 6 DL-Lactic F c ↑ C 7 Maleic 0 ↑ C 8 Malonic F c ↑C 9 Mandelic 0 NC 10 Methanesulfonic NC NC 11 Oxalic 0 0 + X 12 Salicylic 0 ↑ C 13 Succinic F c ↑C 14 L- Tartaric 0 d 0 + X 15 p- Toluenesulfonic NC NC 16 Control P f NC TABLE 5 key: aT0; after storage overnight at RT (Ar; light-protected); after recording appearances, solvent was removed from each vial (Rotavap), which was then flushed with Ar and stored at RT (light-protected) bsee photo in FIG. 22. Vials (left-to-right) contain acids listed in descending order c faint color; DL-Lactic > glycolic = fumaric = malonic = succinic d white ppt present e filtrate f Control > t-cinnamic g T1 (day 1); deepening color/development of color not evident (NC); there were no noticeable changes at T2 (day 2) h appearances recorded after addition of 200 mL EtOH 0 = colorless solution F = faintly colored solution P = purple solution V = violet solution CS = colored solution ↑ = deeper color X = crystals present -
FIG. 22 was taken at an 18-hour timepoint and demonstrates visually that salt formation is effective at improving the stability of psilocin. - A salt screen was performed on psilocin. The salt screen was performed according to the saturated API solution method. 23 counterions were explored in 3 solvent systems. For each counterion, 1.1 molar equivalent was used. In case the counterion had multiple ionization sites, 0.55 molar equivalent was also tested. To (close to) saturated solution of the API in ethanol, acetonitrile, and methyl ethyl ketone, 1M solutions of the counterion was added. With ACN solutions, aqueous counterion solutions were used, and with EtOH and MEK, counterion solutions prepared in THF were used. The mixtures were kept at RT overnight and than equilibrated at 5° C. for 3 days. Solids and liquids were separated. Solids were analyzed by XRPD wet and after drying under vacuum. The solvents were evaporated and obtained solids were analyzed by XRPD.
- A benzoate salt was recovered.
FIG. 25A shows XRPD patterns of benzoate salt Ben1 compared to psilocin free base and benzoic acid.FIG. 25B shows the vacuum dried benzoate salt. - A besylate salt was recovered.
FIG. 26A shows XRPD patterns of potential besylate salt Bes1 compared to psilocin free base and benzenesulfonic acid.FIG. 26B shows the vacuum dried besylate salt. - Fumarate salts were recovered.
FIG. 27A shows XRPD patterns of the fumarate salts compared to psilocin free base and fumaric acid. Fum1a and Fum1b were obtained as vacuum dry solids. Fum2 and Fum3 were only observed in the wet solids and converted to Fum1b upon drying Fum1a and Fum1b were observed in samples performed with both 1 and 0.5 molar equivalent of fumaric acid, Fum2 and Fum3 were only observed when 0.5 molar equivalent of fumaric acid was used.FIGS. 27B-27E show the different fumarate salts. - A glutarate salt was recovered.
FIG. 28A shows XRPD patterns of glutarate salt Glt1 compared to psilocin free base and glutaric acid.FIG. 28B shows the wet glutarate salt andFIG. 28C shows vacuum dried glutarate salt. - A lactate salt was recovered.
FIG. 29A shows XRPD patterns of lactate salt Lac1 compared to psilocin free base and lactic acid.FIG. 29B shows the vacuum dried lactate salt. - A malonate salt was recovered.
FIG. 30A shows XRPD patterns of potential malonate salt Mao1 compared to psilocin free base and malonic acid.FIG. 30B shows the vacuum dried malonate salt. - Oxalate salts were recovered.
FIG. 31A shows XRPD patterns of the oxalate salts compared to psilocin free base and oxalic acid. Oxa1a and Oxa1b were obtained from experiments performed with 1 molar equivalent oxalic acid, while the other oxalate salts were obtained from experiments with 0.5 molar equivalent.FIGS. 31B-31G show the different oxalate salts. - A phosphate salt was recovered.
FIG. 32A shows XRPD patterns of phosphate salt Pho1 compared to psilocin free base.FIG. 32B shows the vacuum dried phosphate salt. - Succinate salts were recovered.
FIG. 33A shows XRPD patterns of succinate salts compared to psilocin free base and succinic acid. Suc1 was obtained from the experiments performed in MEK (both ratios), and Suc2 was obtained from the experiment performed with 0.5 molar equivalent succinic acid in ACN and converted to Suc3 upon drying.FIGS. 33B-33D show the different succinate salts. - Two tartrate forms were identified, Tar1 and Tar2. The thermal stability of the psilocin tartrate salt was evaluated in four solvent systems: water, water/
ACN 50/50, Water/THF 50/50 and water/1,4-dioxane 50/50. Solutions of API and tartaric acid were prepared in the selected solvents. These solutions were measured by UPLC-MS and re-measured after storage at 5° C. overnight. The results indicated that the API remains stable in water and 50% water solutions in presence of 1 molar equivalent of tartaric acid. -
TABLE 6 Temp., time RT Area Purity Area Solvent (° C., h) (min) (mAu*s) (%) Water RT, t0 1.32 2513.54 99.1 Water 5° C., 18 h 1.32 2555.19 99.0 Water/ Acetonitrile 50/50RT, t0 1.33 2102.77 99.0 Water/ Acetonitrile 50/505° C., 18 h 1.33 2109.21 99.0 Water/ THF 50/50RT, t0 1.32 2581.10 99.1 Water/ THF 50/505° C., 18 h 1.30 4312.55 99.0 Water/1,4- Dioxane 50/50RT, t0 1.32 2335.92 98.9 Water/1,4- Dioxane 50/505° C., 18 h 1.25 10262.35 99.0 -
FIG. 34 shows a comparison of the XRD patterns for psilocin free base, psilocin tartrate salt Form 1 (Tar1), psilocin tartrate salt Form 2 (Tar2) and three examples of amorphous psilocin tartrate salt (Am). 20 mg of API and 15 mg of tartaric acid were weighed in vials (molar ratio 1:1). Aliquots of 100 μL solvent were added until the solids were dissolved. The obtained solutions were frozen in liquid nitrogen and placed in the freeze dryer overnight. From water, water/THF 50/50 and water/dioxane 50/50 amorphous solids were recovered. The solid from water contained 1.3% residual water, while the solids obtained from the THF and dioxane mixtures contained 7.8 and 10.3% solvent, respectively. The solid obtained from the acetonitrile mixture was crystalline and had a different XRPD than the free base or the already known tartrate salt and was designated Tar2. All solids had a purity of about 99%. The material to be used for polymorph screening was prepared by freeze drying a solution in water. -
FIG. 35 is an overlay comparing the XRPD pattern of psilocin tartrate salt Form 1 (Tar1) and Form 2 (Tar2). TCP13 was isolated from acetone/water, 95:5 as follows. To about 35 mg of amorphous psilocin tartrate salt, acetone/water (95:5) was added in small aliquots until a thin suspension was obtained. The suspension was subjected to a temperature cycling profile, of 3 cycles between 5 and 50° C. with a heating rate of 10° C./h and cooling rates of 20, 10 and 5° C./h, with a final aging stage at 25° C. for 48 hours. The solids were isolated and analyzed by XRPD after drying at ambient conditions and under vacuum at 50 C. The gently dried and harshly dried solids had the same XRPD patterns. - TABLE 7 shows high throughput XRPD peak information for Tar1 and TABLE 8 shows high throughput XRPD peak information for Tar2. XRPD peak information from high resolution XRPD may vary from that presented in these tables.
-
TABLE 7 Peak ID Angle (2θ) d- Spacing Intensity 1 13.42 6.59 28.9 2 14.7 6.02 33.71 3 17.22 5.14 100 4 18.78 4.72 51.09 5 20.02 4.43 55.4 6 20.82 4.26 28.38 7 21.78 4.08 53.7 8 22.54 3.94 69.37 9 24.7 3.6 37.17 10 25.46 3.49 29.16 11 26.58 3.35 28.75 12 28.5 3.13 23.05 13 30.94 2.89 20.16 -
TABLE 8 Peak ID Angle (2θ) d- Spacing Intensity 1 10.22 8.65 39.16 2 13.1 6.75 38.3 3 15.38 5.75 46.83 4 16.26 5.44 72.52 5 17.54 5.05 89.84 6 18.02 4.92 46.48 7 19.46 4.56 94.32 8 20.54 4.32 87.82 9 23.46 3.79 99.98 10 24.46 3.63 70.26 11 26.14 3.4 33.91 12 27.06 3.29 51 13 31.1 2.87 37.28 14 35.9 2.5 27.97 -
FIG. 36A shows an XPRD graph of Whole Powder Pattern Decomposition analysis of the tartrate salt Tar1. The refinement data and cell parameters are shown in TABLE 9. -
TABLE 9 Experiment ID TCP11 Polymorph Psilocin Tartrate Empirical formula C12H17N2O+ C4H5O6− Formula weight 354.36 T [K] 296 lambda[Å] 1.54056 Crystal system Orthorhombic Proposed space group P212121 Unit cell dimensions a[Å] 7.5944(9) b[Å] 8.2458(9) c[Å] 26.4419(18) V[Å3] 1655.8(3) Z (Z′) 4(1) Dc [g/cm3] 1.421 Cap. size [mm2] 0.3 × 8 2theta Step size [°] 0.0157 No of steps 2500 Time per step [s] 10 2theta range [°] 2.15-41.5 Rexp 2.32 Rwp 3.26 Rp 2.54 GOF 1.40 RBrag 0.16 Impurities, other forms [%] Below detection limits -
FIG. 36B shows the polarized light microscopy image taken with 20× magnification. The solid consists of small needle like crystals with longest size close to 0.05 mm that are arranged in aggregates looking like hay sheaves. - XPRD peak data is shown in TABLE 10.
-
TABLE 10 Peak ID Angle (2θ) d- Spacing Intensity 1 6.67 13.24 3 2 11.22 7.88 1 3 12.64 7.00 6 4 13.40 6.60 13 5 14.71 6.02 23 6 15.86 5.58 12 7 16.20 5.47 6 8 17.23 5.14 100 9 18.80 4.72 43 10 19.94 4.45 36 11 20.15 4.40 31 12 20.81 4.27 14 13 21.82 4.07 37 14 22.58 3.93 57 15 22.86 3.89 6 16 23.15 3.84 6 17 23.41 3.80 14 18 23.67 3.76 13 19 24.57 3.62 14 20 24.78 3.59 21 21 25.48 3.49 16 22 25.73 3.46 6 23 26.02 3.42 3 24 26.60 3.35 16 -
FIG. 37A shows an XPRD graph of Whole Powder Pattern Decomposition analysis of the tartrate salt Tar2. The refinement data and cell parameters are shown in TABLE 11. -
TABLE 11 Experiment ID TCP12 Polymorph Psilocin Tartrate 0.3 hydrate Empirical formula C12H17N2O+ C4H5O6 − 0.3 H2O Formula weight 359.76 T [K] 296 lambda[Å] 1.54056 Crystal system Monoclinic Proposed space group C2 Unit cell dimensions a[Å] 27.0989(21) b[Å] 7.5302(3) c[Å] 17.5540(12) V[Å3] 99.516(3) Z (Z′) 3532.8(4) Dc [g/cm3] 8(2) Cap. size [mm2] 1.353 2theta Step size [°] 0.7 × 8 No of steps 0.0157 Time per step [s] 2500 2theta range [°] 5 Rexp 2.15-41.5 Rwp 2.92 Rp 3.62 GOF 2.78 RBrag 1.24 Impurities, other forms [%] 0.31 -
FIG. 37B shows the polarized light microscopy image taken with 10× magnification. The solid consists of small needle like crystals with longest size close to 0.05 mm that are arranged in aggregates looking like hay sheaves. - XPRD peak data are shown in TABLE 12.
-
TABLE 12 Peak ID Angle (2θ) d- Spacing Intensity 1 5.08 17.37 2 2 6.61 13.36 2 3 9.02 9.80 1 4 10.21 8.65 23 5 11.22 7.88 3 6 13.07 6.77 11 7 13.41 6.60 3 8 14.97 5.91 4 9 15.36 5.76 28 10 15.59 5.68 15 11 16.29 5.44 51 12 16.74 5.29 2 13 17.57 5.04 100 14 18.05 4.91 20 15 19.41 4.57 67 16 19.73 4.50 17 17 19.92 4.45 29 18 20.51 4.33 76 19 20.85 4.26 21 20 22.57 3.94 8 21 23.45 3.79 81 22 23.65 3.76 18 23 23.90 3.72 5 24 24.40 3.65 52 - Rietveld analysis of psilocin as received, using CCDC 1238288 single crystal data as a model is shown in
FIG. 38A . - The experimental conditions and cell parameters are shown in TABLE 13.
-
TABLE 13 Compound Psilocin Polymorph Form A Empirical formula C12H16N2O Formula weight 204.27 T [K] 296(2) K lambda[Å] 1.54056 Crystal system Monoclinic Space group P21/c Cap. size [mm2] 0.5 × 8 2theta Step size [°] 0.016 No of steps 2503 Time per step [s] 15 2theta range [°] 2.15→ 41.5 Rexp 3.05 Rwp 5.31 Rp 4.01 GOF 1.74 RBrag 2.05 Impurities, other forms [%] Below Detection Limits -
FIG. 38B shows the polarized light microscopy image taken with 20× magnification. The solid consists of plate like crystals with the longest sizes close to 0.05 mm. - XPRD peak values are shown in TABLE 14.
-
TABLE 14 Peak table for Psilocin Form A Peak ID Angle (2θ) d- Spacing Intensity 1 8.35 10.58 29 2 12.59 7.02 11 3 13.34 6.63 6 4 14.21 6.23 1 5 15.06 5.88 5 6 15.18 5.83 8 7 16.38 5.41 1 8 16.73 5.30 15 9 17.63 5.03 13 10 19.42 4.57 33 11 19.62 4.52 100 12 20.87 4.25 16 13 21.08 4.21 18 14 21.81 4.07 4 15 22.19 4.00 2 16 22.50 3.95 5 17 23.65 3.76 50 18 24.23 3.67 1 19 24.55 3.62 1 20 25.39 3.51 3 21 26.77 3.33 10 -
FIG. 39 shows an asymmetric unit of psilocin tartrate crystal (Tar1), with the hydrogen bond shown between the two molecules. The charged N3 atom interacts in bifurcated hydrogen bonds. One interaction is directed toward the carboxylic non deprotonated acidic group, while the second interaction is directed toward the (deprotonated) acidic carboxylate group. The N—H group from the fused ring act as H-bond donor to the hydroxyl group of the anion closer to the carboxylate (O27) as acceptor. The crystal is built up by an extensive hydrogen bonds network, where each N or O connected H atom is utilized as donor of hydrogen bonds, while every O atom serves as hydrogen bonds acceptor. TABLE 15 shows crystallographic parameters. -
TABLE 15 Form Psylocin tartrate (Tar1) Empirical formula C16H22N2O+ C4H5O6 − Formula weight 354.35 T [K] 296(2) K λ [Å] 0.71073 Å Crystal system Orthorhombic Space group P2 12121 Unit cell dimensions a [Å] 26.4225(9) b [Å] 7.5909(4) c [Å] 8.2544(3) β [°] — V[Å3] 1655.59(12) Z(z′) 4 Dc [g/cm3] 1.422 μ [mm−1] 0.112 F(000) 752 Crystal size [mm3] 0.45 × 0.28 × 0.02 θ range for data collection [°] 2.6 → 32.6 Reflections collected 12971 Independent reflections 5664 [R(int) = 0.0462] Completeness to θ = 22.0° [%] 99.5% Absorption correction Semi-empirical from equivalents Max. and min. transmission 0.998 and 0.736 Data/restraints/parameters 5664/0/251 Goodness-of-fit on F2 0.901 Final R indices [I > 2σ(I)] R1 = 0.0414, wR2 = 0.0900 R indices (all data) R1 = 0.0795, wR2 = 0.1008 Absolute structure parameter 1.3(8) Extinction coefficient n/a Largest diff. peak and hole [e/Å3] 0.145 and −0.163 - A HR-XRPD pattern was collected using the crushed crystals that were obtained by evaporation from ethanol. Comparison of this HR-XRPD pattern with the simulated XRPD from the single crystal data confirmed that the patterns were identical. Rietveld analysis was performed on the HR-XRPD data, using the single crystal data as model. No crystalline impurities were detected (
FIG. 40 , TABLE 16). The top lines represent collected data and calculated and the bottom line is the difference between them. The sticks at the bottom show the peak positions of the unit cell. -
TABLE 16 Form Psilocin Tartrate Monohydrate Empirical formula C16H22N2O+ C4H5O6 − Formula weight 354.35 T [K] 296 λ[Å] 1.54056 Crystal system Orthorhombic Space group P2 12121 Cap. size [mm2] 0.5 × 8 2θ Step size [°] 0.016 No of steps 2499 Time per step [s] 5 2θ range [°] 2.15.41.5 Rexp 1.13 Rwp 2.20 Rp 1.60 GOF 1.94 RBrag 1.46 Impurities, other forms [%] Below detection limit - Evaporation of the mother liquor of a salt screen experiment performed with 1.1 molar equivalent of hydrobromic acid in MEK resulted in the recovery of HBr1. The HT-XRPD pattern of the solid are shown in
FIG. 41A . HBr1 was unstable upon exposure to AAC for two days and became deliquescent.FIG. 41B shows an image of the material of HBr1. - The UPLC analysis of HBr1 (
FIG. 42 ) showed the presence of the API peak with the chemical purity of 70.6% (area %). The peak at 1.5 min corresponded to a m/z of 277 (M+72)+, possibly due to a reaction of API with MEK. - The TGMS analysis of HBr1 (
FIG. 43 ) showed a mass loss of 4.7% in the range 25-180° C., which could correspond to 0.20 MEK molecules per API salt unit. The DSC trace of HBr1 (FIG. 44 ) showed two endothermic events at 88.1° C. and at 145.6° C., possibly related to the mass loss observed by TGMS analysis and melting, respectively. The 1H-NMR spectrum of HBr1 is shown inFIG. 45 . The API peaks shifted compared to the free base, confirming salt formation took place. Since hydrobromic acid is an inorganic counterion, the stoichiometry was not confirmed. About 0.4 molar equivalent of MEK were detected (or 9.2%). - Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
- The invention has been described in an illustrative manner, and it is to be understood that the terminology, which has been used is intended to be in the nature of words of description rather than of limitation.
- Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/883,509 US20220370413A1 (en) | 2021-03-06 | 2022-08-08 | Formulations of psilocin that have enhanced stability |
US18/326,480 US20230285359A1 (en) | 2021-03-06 | 2023-05-31 | Formulations of psilocin that have enhanced stability |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163157682P | 2021-03-06 | 2021-03-06 | |
US202163184691P | 2021-05-05 | 2021-05-05 | |
US17/687,568 US20220280482A1 (en) | 2021-03-06 | 2022-03-04 | Formulations of psilocin that have enhanced stability |
US17/883,509 US20220370413A1 (en) | 2021-03-06 | 2022-08-08 | Formulations of psilocin that have enhanced stability |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/687,568 Continuation-In-Part US20220280482A1 (en) | 2021-03-06 | 2022-03-04 | Formulations of psilocin that have enhanced stability |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/326,480 Continuation US20230285359A1 (en) | 2021-03-06 | 2023-05-31 | Formulations of psilocin that have enhanced stability |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220370413A1 true US20220370413A1 (en) | 2022-11-24 |
Family
ID=84102566
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/883,509 Pending US20220370413A1 (en) | 2021-03-06 | 2022-08-08 | Formulations of psilocin that have enhanced stability |
US18/326,480 Pending US20230285359A1 (en) | 2021-03-06 | 2023-05-31 | Formulations of psilocin that have enhanced stability |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/326,480 Pending US20230285359A1 (en) | 2021-03-06 | 2023-05-31 | Formulations of psilocin that have enhanced stability |
Country Status (1)
Country | Link |
---|---|
US (2) | US20220370413A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023168023A1 (en) * | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
WO2024015447A1 (en) * | 2022-07-12 | 2024-01-18 | Lobe Sciences Ltd. | Preparation of stable psilocin salts, esters and conjugates and uses thereof |
US11958807B2 (en) | 2020-05-19 | 2024-04-16 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
EP4417198A1 (en) | 2023-02-14 | 2024-08-21 | MYOB GmbH in Gründung | Pharmaceutical compositions comprising a psychedelic drug and a dendritic nanocarrier |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11312684B1 (en) * | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
US11591353B2 (en) * | 2020-02-04 | 2023-02-28 | Mindset Pharma Inc. | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
-
2022
- 2022-08-08 US US17/883,509 patent/US20220370413A1/en active Pending
-
2023
- 2023-05-31 US US18/326,480 patent/US20230285359A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11591353B2 (en) * | 2020-02-04 | 2023-02-28 | Mindset Pharma Inc. | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
US11312684B1 (en) * | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
Non-Patent Citations (1)
Title |
---|
Saal, C. et al., Pharmaceutical salts: a summary on doses of salt formers from the orange book, 5 June 2013, European Journal of Pharmaceutical Sciences, Vol. 49, 614-623 (Year: 2013) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11958807B2 (en) | 2020-05-19 | 2024-04-16 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2023168023A1 (en) * | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
WO2024015447A1 (en) * | 2022-07-12 | 2024-01-18 | Lobe Sciences Ltd. | Preparation of stable psilocin salts, esters and conjugates and uses thereof |
EP4417198A1 (en) | 2023-02-14 | 2024-08-21 | MYOB GmbH in Gründung | Pharmaceutical compositions comprising a psychedelic drug and a dendritic nanocarrier |
Also Published As
Publication number | Publication date |
---|---|
US20230285359A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220370413A1 (en) | Formulations of psilocin that have enhanced stability | |
US20220280482A1 (en) | Formulations of psilocin that have enhanced stability | |
McInnes et al. | Solid state stabilisation of the orally delivered drugs atenolol, glibenclamide, memantine and paracetamol through their complexation with cucurbit [7] uril | |
JP7429013B2 (en) | New solid forms of cannabidiol and their uses | |
US11291652B2 (en) | Glycopyrrolate salts | |
BR112015004135B1 (en) | CRYSTALLINE FORMS OF 1- (5 '- (5- (3,5-DICLORO-4-FLUOROFENYL) -5- (TRIFLUOROMETHIL) -4,5-DIHIDROISOXAZOL-3-IL) -3'H-SPIRUS [AZETIDINE-3 , 1'-ISOBENZOFURAN] -1-IL) -2- (METHYLSULFONY) ETANONE, ITS COMPOSITION, ITS USE AND ITS PREPARATION PROCESS | |
EP3473615A1 (en) | Glycopyrrolate salts | |
US6242460B1 (en) | Zolpidem salt forms | |
JPWO2018181847A1 (en) | Aromatic compounds | |
WO2012137111A1 (en) | Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer | |
KR102597117B1 (en) | IP6K inhibitor | |
AU2014239254B2 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
CA2887913A1 (en) | Multifunctional radical quenchers | |
ES2577391T3 (en) | Polymorphs of an mglur5 receptor antagonist | |
TWI703143B (en) | Crystalline forms of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro〔 indazole-5,4'-piperidine 〕-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid | |
CN116507613A (en) | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | |
KR20170033684A (en) | Crystalline form of linagliptin and preparation method thereof | |
US20120283274A1 (en) | Crystalline forms of substituted pyrazolopyrimidines | |
EP4296670A2 (en) | Sulfopropanoic acid derivatives for treating neurodegenerative disorders | |
CA3035161A1 (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
US20230257385A1 (en) | Salt and solid forms of tabernanthalog | |
US20140128444A1 (en) | Novel crystalline salts of asenapine with organic di-acids and tri-acids | |
EP2551257A1 (en) | Co-crystals of agomelatine with co-crystal-formers | |
KR20240019116A (en) | (3R)-N-[2-Cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1 -New solid form of sulfonamide | |
RU2270834C2 (en) | Therapeutic compound citric acid salt and pharmaceutical compositions based on thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MIND MEDICINE, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARROW, ROBERT;MACK, PETER;SCHNEIDER, STEPHEN;AND OTHERS;SIGNING DATES FROM 20220930 TO 20221003;REEL/FRAME:061406/0151 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |